Pharmaceutical - Mergers & Acquisitions, Antibiotics and Infectious diseases


Popular Filters

Actavis to acquire Durata Therapeutics for $675 million

Actavis to acquire Durata Therapeutics for $675 million


In a move that takes it further out of its main generics business, Ireland-headquartered Actavis has…

ActavisAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsIrelandMergers & AcquisitionsPharmaceutical

Transcept and Paratek join forces in reverse takeover

Transcept and Paratek join forces in reverse takeover


US pharma company Transcept Pharmaceuticals and privately-held biopharmaceutical company Paratek Pharmaceuticals…

Antibiotics and Infectious diseasesMergers & AcquisitionsParatek PharmaceuticalsPharmaceuticalTranscept PharmaUSA

Evotec to acquire Euprotec to establish an anti-infectives platform

Evotec to acquire Euprotec to establish an anti-infectives platform


Germany’s Evotec says it has acquired all the shares in Euprotec Ltd, a UK-based specialist contract…

Anti-infective drug discovery servicesAntibiotics and Infectious diseasesBusiness FinanceDiseaseEvotecHealth Medical PharmaMergers & AcquisitionsPharmaceuticalRecognised leader

Debiopharm to acquire Affinium's antibiotic clinical assets and platform


Swiss drug developer Debiopharm Group has entered into an agreement to acquire Canadian venture capital…

Affinium PharmaceuticalsAFN-1720Antibiotics and Infectious diseasesDebiopharmMergers & AcquisitionsPharmaceutical

Astellas partners with ClearPath to build vaccine portfolio; sells fermentation assets

Astellas partners with ClearPath to build vaccine portfolio; sells fermentation assets


Japanese drug major Astellas Pharma has entered into a strategic partnership with ClearPath Development…

Antibiotics and Infectious diseasesAstellas PharmaClearPath DevelopmentLicensingMergers & AcquisitionsMymetics CorpOtsukaPharmaceuticalRSV CorpTaiho Pharmaceutical

The Medicines Company acquires antibiotics maker Rempex Pharma


USA-based The Medicines Company has acquired Rempex Pharmaceuticals, a company with multiple potential…

Antibiotics and Infectious diseasesMergers & AcquisitionsPharmaceuticalRempex PharmaceuticalsThe Medicines Company

Cubist Pharma signs two acquisition deals in one day


In what must have been a busy day for US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) announced not…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMergers & AcquisitionsOptimer PharmaceuticalsPharmaceuticaltedizolidTrius Therapeutics

Briefs: Boehringer files Pradaxa for DVT and PE; Astellas' Mycamine pediatric approval; Simcere divests Boda


Family-owned German drug major Boehringer Ingelheim has submitted an application to the European Medicines…

Antibiotics and Infectious diseasesAstellas PharmaBoehringer IngelheimCardio-vascularEuropeJilin BodaMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationSimcere PharmaceuticalYidashen

Grifols gains global rights to Aradigm's Pulmaquin


Spanish drugmaker Grifols (GRLS: MC) has signed an exclusive, worldwide license for USA-based Aradigm's…

Antibiotics and Infectious diseasesAradigmCiprofloxacinGrifolsLicensingMergers & AcquisitionsPharmaceuticalPulmaquinRespiratory and Pulmonary

Novo A/S acquires Norway's Xellia Pharmaceuticals in $700 million deal


Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in Novo Nordisk…

Antibiotics and Infectious diseasesGenericsMergers & AcquisitionsNovo A/SNovo NordiskPharmaceuticalXellia Pharmaceuticals

MicuRx joins forces with VC for next-generation antibiotic for China


MicuRx Pharmaceuticals, a privately-held US biopharmaceutical company developing next-generation antibiotics,…

Antibiotics and Infectious diseasesAsia-PacificMergers & AcquisitionsMicuRx PharmaceuticalsMRX-IPharmaceuticalResearchShanghai MengKe Pharma

Forest acquires rights to Nabriva antibacterial and option to buy firm


US drugmaker Forest Laboratories (NYSE: FRX) says it has entered into an agreement with Austrian biotech…

Antibiotics and Infectious diseasesBC-3781BiotechnologyForest LaboratoriesLicensingMergers & AcquisitionsNabriva TherapeuticsPharmaceutical

News briefs: GlaxoSmithKline and Bayer


UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Teva settles Nuvigil patent litigation with Mylan, which debuts generic Doryx


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world's largest generics companies, said…

Antibiotics and Infectious diseasesDoryxGenericsLegalMergers & AcquisitionsMylan LaboratoriesNeurologicalNorth AmericaNuvigilPatentsPharmaceuticalTeva Pharmaceutical IndustriesWarner Chilcott



Back to top